Hepatocellular Carcinoma: Focus on Different Aspects of Management by Waly Raphael, Sene et al.
International Scholarly Research Network
ISRN Oncology
Volume 2012, Article ID 421673, 12 pages
doi:10.5402/2012/421673
Review Article
Hepatocellular Carcinoma: Focus on
DifferentAspects of Management
Sene Waly Raphael, ZhangYangde, andChen YuXiang
National Hepatobiliary and Enteric Surgery Research Center of Ministry of Health, Central South University, Changsha,
Hunan 410008, China
Correspondence should be addressed to Zhang Yangde, zyd99@189.cn
Received 8 January 2012; Accepted 4 March 2012
Academic Editor: T. Yokoe
Copyright © 2012 Sene Waly Raphael et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Hepatocellular carcinoma (HCC) is the ﬁfth most common cancer and the third cause of cancer-related mortality worldwide. Its
incidence is clearly arising comprised by the prevalence of major risk factors mainly hepatitis B and hepatitis C. The population at
riskis composed of chronic liver patients at the stage of extensive ﬁbrosis or cirrhosis.Themonitoring programs of this population
have allowed early detection of disease management to promote a radical therapy. Understanding the carcinogenic process and
the mastery of the staging systems remain essential keys in diagnosis and treatment of HCC. Recent advances in diagnosis and
new treatments have made important impacts on the disease by increasing survival rates and improving quality of life for HCC
patients. This paper outlines the diﬀerent management aspects of HCC which include epidemiology, prevention, carcinogenesis,
staging systems, diagnosis, surveillance, and the treatment.
1. HCCEpidemiology
HCC is the most common primary liver cancer. The annual
number of new cases of HCC worldwide is over one million,
making it the 5th most common cancer worldwide and the
3rd leading cause of cancer-related death, preceded only by
the lung and stomach cancers [1–6]. The global distribution
varies by region due to factors at the origin of the disease.
HCC is an end result of some chronic infections with the
hepatitis B (HBV) or the hepatitis C (HCV) Figure 1 [7–9].
More than 80% of HCCs develop in Asian and African coun-
tries where between 40% and 90% of HCCs are attributable
to chronic hepatitis B [1, 10]. China especially comprises
more than half the rate of new cases recorded with over 55%
(around 120 million people in China are carriers of the HBV
correspondingtoalmostathirdofpeopleinfectedworldwide
[11, 12]. In Singapore, Japan, and Australia/New Zealand,
HCC infection is exceptionally due to the high incidence
of HVC infections [13–15]. Prevalence of HCV infections is
reported to be the main leading cause of HCC in Europe and
also in the United States where the incidence is relatively low.
Currently, there are an estimated 3 million people in United
States with chronic hepatitis C; these patients are estimated
to develop HCC at a rate of 0.5% to 5% per year [12]. In
Europe,theincidenceofHCVmayberelatedtotheextensive
campaign to vaccinate children in the years 1940s to 1950s
and possibility to inadequate sterilization of nondisposable
needles and syringes up to the mid-1970s. Those infected
with hepatitis C during this period have now been infected
for 30 years and therefore have signiﬁcantly increased risk
of having established cirrhosis. Thus, the silent hepatitis C
epidemic from that area is the likely cause of the increase in
HCC incidence in those parts of the world [16]. In Africa,
exceptionally in Egypt, HCV is the most leading increase in
HCC. Egypt is known for being the country in the world
where the rate of HCV is higher, about 24% of the people
are estimated to carry HCV and the more than 50% of blood
donors have anti-HCV in some towns [17]. Between 1993
and 2002, there was an almost twofold increase in HCC
amongst chronic liver patients [2]. Men are more likely to
be aﬀected than women with HCC [18]. This trend was
observed in almost all countries. Therefore, it was noted in
some European countries such as Switzerland (male:female:
4:1), Italy (male:female: 5:1), France (male:female: 5:1);2 ISRN Oncology
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Figure 1: The striking parallel geographical distribution of the incidence of chronic hepatitis B virus infection and that of hepatocellular
carcinoma. (Source [6] with permission of the Pathologie Biologie Journal.)
in the developing states, the ratio is more equal, for example,
China 3:1, Gambia 2.8:1, and Zimbabwe 2.4:1 [5, 19].
In Japan, the male/female ratio was 4.5 between 1984 and
1985 and 2.5 between 2002 and 2003 [15]. The reasons of
these trends are not well understood but several factors may
explain that. Males are more likely to be infected with HBV
and HCV, in addition cigarettes smoker, and alcohol con-
sumer have a higher body mass index (BMI). Testosterone
ratehasbeenshowntocorrelatewithHCCindicatingaprob-
able role for the sex hormones in the development of HCC.
IL-6isthought tobeimplicated, asIL-6disruption abolished
the gender diﬀerences in hepatocarcinogenesis [3, 5, 19].
1.1. Risk Factors. Besides HCV and HBV, other risk factors
have been reported to be involved in the development of
HCC. Any agent leading to chronic injury and eventually
cirrhosisconstitutesanoncogenicagent[20].Aﬂatoxin(AF),
alcoholism, and nonalcoholic steatohepatitis (NASH) are
important and prevalent in certain areas of the world.
1.2. Cirrhosis. Cirrhosis is an end stage of chronic diﬀuse
liver disease. It is characterized by alteration of the normal
liver into structurally abnormal nodules of liver cells sur-
rounded by ﬁbrosis. The changes must be diﬀuse throughout
the liver. The risk of cancer development from chronic or
cirrhosis varies according to the degree of ﬁbrosis [21]. Main
causes of liver cirrhosis are alcohol use, chronic hepatitis B
and C, and nonalcoholic steatohepatitis [22–25].
Cirrhosis is present in 80–90% of HCC patients and is
thereby the largest single risk factor [19]. With exception of
HBV and AF, all other etiological risk factors are associated
with cirrhosis. It is generally believed that the majority
of HCCs develop in a progressively from acute hepatitis
through various stages of chronic hepatitis, to cirrhosis, to
HCC [26].
1.3. Alcohol Intake. The frequency of HCC in alcoholics is
rather low and far less than that of tumors of the upper
digestive tract [27]. No agreement exists on the dose-eﬀect
relationship between alcohol intake and risk of HCC, but
some experts deﬁned it as a proven risk factor for HCC when
the daily consumption is estimated at 50 to 75g per day.
It has not been proven eﬀective carcinogen direct alcohol
on the occurrence of HCC, but rather an indirect eﬀect
through repeated injuries progressing to extensive ﬁbrosis
and cirrhosis. Some mechanisms such as chromosomal loss,
oxidative stress, a decreased retinoic acid level in the liver,
altered DNA methylation, and genetic susceptibility can
be regarded as causes of alcohol leading to HCC [28–39].
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in the world.
1.4.Aﬂatoxin(AF). Aﬂatoxinisbelievedtobeamajorcausa-
tive agent in the high incidence of primary liver cancer seen
in certain regions of the world. In some Africa and Asia
regions especially, it is known to be a key risk factors of
HCC. Aﬂatoxins are a group of approximately 20 related
fungal metabolites with four major known as B1, B2, G1,
and G2. Among them, B1 is the most potent naturally occur-
ring chemical liver disease carcinogen known [31]. They are
produced by Aspergillus ﬂavus and related fungus that grow
on improperly stored foods, such as corn, rice, and peanuts.
Eﬀects of aﬂatoxin carcinogen result in p53 gene mutations.
Generally, in human cancer, in more than 50% of tumors,
p53 is mutated and these mutations occur at the third
position of codon 249 with the GC—TA transversion [32,
33]. Associated with HBV, dietary exposure to aﬂatoxin in-
crease the HCC risk factors [34].
1.5. Nonalcoholic Steatohepatitis (NASH). Nonalcoholic ste-
atohepatitis was originally believed to be a benign disease,
but it has been recently revealed that NASH could lead to
irreversible liver diseases [35]. NASH is a term used to des-
cribe a spectrum of conditions characterized by histological
ﬁndings of hepatic macrovascular steatosis with inﬂamma-
tion in individuals who consume little or no alcohol [36].
It is part of the spectrum of nonalcoholic fatty liver disease
(NAFLD) that can lead to cirrhosis in patients without a
history of alcohol abuse and whose prevalence is increasing
in Western countries because of the obesity and diabetes
mellitus incidence. 20% of NASH cases generally progress to
cirrhosisandresultincomplicationsincludingHCC[37,38].
Hedgehog (Hh) pathway activation and NKT (natural killer
T) cells seem to be involved in the development of NASH-
related liver ﬁbrosis. The liver’s response to damage due to
fat accumulation is modulated by these cells. Bugianesis [39]
proves that the activation of the liver NKT cells generates
soluble factors that promote ﬁbrogenesis via a mechanism
involving myoﬁbroblastic activation of hepatic stellate cells.
2. HCC Prevention
Since chronic viral B and C are known to be the most com-
mon causes of carcinogenesis, prevention of HCC requires
an eﬀective risk control of infection due to these factors.
Therefore, vaccination against the hepatitis B virus appears
the best way for prevention [40–42]. In chronic HBV infec-
tion, mother-to-child transmission generally accounts for 35
to 50% through exposure to blood or blood-contaminated
ﬂuids at or around birth. Approximately 70 to 90% of the
infants of the HBeAg-seropositive carriers mothers became
HBsAg carriers [13, 43]. Routine vaccination at birth in
countries with high prevalence of HBV infection can reduce
the transmission. In Taiwan, where the world’s ﬁrst universal
hepatitis vaccination program was conducted in July 1984,
chronic HBV infection in mother-to-infant transmission has
decreased from 86–96% to 12–14% [44]. As a consequence
a reduction in the incidence of HCC was noted. Success in
mass program vaccination has been seen in Thailand and
Singapore [45]. In western countries, universal vaccination
has been adopted, and, in developing countries, mass vac-
cination programs are being introduced. These programs
shouldleadincomingdecadestosigniﬁcantdecreaseinHCC
incidence [3]. In case of persons already infected chronically
with a HCC risk development, appropriate way is to select
patient at risk for treatment and not a mass vaccination [46].
There is no vaccine available for HCV due to its high
mutation during viral replication. Prevention of HCV infec-
tion requires the reduction of risky behavior and the im-
provement of hygiene by the widespread use of disposable
syringes and needless reduction of transmission among in-
jectingdrugusersandalsothescreeningofblooddonorsand
organ donors [47, 48].
Reduction of alcohol consumption in HCV-infected pa-
tients,controllingobesityanddiabetesmellitus,limitingfun-
galcontaminationofcropseitherpre-orpostharvestedtore-
duce aﬂatoxin exposure are also measures that could have a
real eﬀect on HCC risk.
Some chemoprevention agents are also used in the HCC
prevention. They diﬀer by country but also the underlying
disease and the results are unreliable according to the desired
eﬀect. They are used to prevent cirrhosis when HCC in non-
HCV-related cirrhosis prevention has been unachievable [3].
Interferon therapy is one of the most used of these agents
against HCC development but their eﬀects are controversial;
studies performed in USA showed that interferon therapy
seems to fail to reduce HCC incidence while in Japan studies
demonstrated a HCC incidence reduction in interferon-
treatedpatients[40].InChina,thecombinationoflavamidin
andravadindemonstratedpromisingresultsinHCCpreven-
tion although the study focused on a reduced patient sample.
Many other agents are in trials, and results should help to
better prevent HCC in certain population groups at risk.
3.MolecularMechanismsof
LiverCarcinogenesis
In humans, 90% HCC cases arise as complication of chro-
nic liver disease/cirrhosis with ﬁbrosis playing a major pre-
disposing role [42]. Molecular mechanisms that lead to the
development of HCC are not well known, but much re-
search is being conducted to better understand these pro-
cesses. So the development of molecular biology has enabled
signiﬁcant progress to improve the knowledge on molecular
mechanisms of carcinogenic. HCC is known to be a result
of the evolution process of a large number of genetic and
epigenetic alterations that some are observed at neoplastic
stages [20, 28, 42, 49]. These alterations aﬀect the proteins in
certain major signaling pathways that control the cycle, pro-
liferation, and cell survival.
3.1. Wnt-β-Catenin Signaling Pathway. Mutations in this
pathway have been described in 20 to 40% of HCC. Wnt-β-
catenin signaling pathway plays a role in all phases of liver
development and maturation which are stem cell renewal,
zonation, cell adhesion, proliferation, diﬀerentiation, liver4 ISRN Oncology
regeneration, and epithelial-mesenchymal transition [50–
52]. HCC occurs frequently through mutations in the N-ter-
minal region of β-catenin that stabilizes the protein and per-
mits an elevation of constitutive transcriptional activation by
β-catenin/TCF complexes [53]. β-catenin mutations seem to
be correlated to the etiology of the HCC. In HBV- and HCV-
related HCC β-catenin mutations, rates are still subject to
discussion. In patients with HBV, β-catenin mutations are
found in lower frequency, unlike HCV-related HCC where
the rate is high at over 40%. In patients without HBV,
the mutations are associated with chromosome stability and
genetic alteration [50, 54].
3.2. Activation of the Insulin-Like Growth Factor (IGF) Sig-
naling Pathway. It is also involved in occurrence of HCC.
The IGF system consists of two ligands, IGF-I and IGF-
II; three cell-membrane receptors, IGF-I receptor (IGF-IR),
insulin receptor (IR), and IGF-II receptor (IGF-IIR); six
high-aﬃnity IGF binding proteins, IGFBP-1 through 6 [55].
An overexpression of the IGF-1 and IGF-2 receptor (IGF-
1R/2R) and silencing of the IGF-binding proteins (IGFBP-
1-5) lead to cascade of molecular events such as cell pro-
liferation, antiapoptosis and invasive behavior [56]. The
activation of this signaling pathway in HCC is initiated
by the IGF II by a loss of promoter-speciﬁc imprinting
and reactivation of fetal promoters, reduced expression of
IGF-binding protein, and/or activation of the IGF II-2R,
which mediates IGF-II degradation. This signaling pathway
seems to have therapeutic interest; by blocking the IGF-
II overexpression, HCC development can be disturbed and
also inhibition of IGF-IR by an antibody or tyrosine kinase
inhibitors HCC cell proliferation can be reduced with or
without apoptosis increase [57].
3.3. The P13/PTEN/AKT. Pathway is involved in several cell-
ular processes such as proliferation, apoptosis, diﬀerentia-
tion, cell motility, cell cycle progression, tumor growth, and
angiogenesis [56, 58]. In experiment in vitro, this pathway
plays a role in HCC cell invasion by enhancing MMP-9
expression[58].Ithasalsoatherapeuticinterestbythekinase
components of the P13K pathway which are essentially
exciting targets for the rational design of small molecules
[59].
3.4. TP53 Tumor Suppressor Gene. The TP53 mutations are
strongly associated to the HCC and considered as the most
consistently mutated tumor suppressor gene in HCC. It
occurs in 30 to 50% hepatocellular carcinomas [60–62]. In
HCC, the TP53 mutations type and frequency are known to
be changing according to the geographic regions of tumors.
Dietary exposure to aﬂatoxin B1 (AFB1) (Africa, Asia) in-
duces mutation in codon 249 by G-T transversion and there-
fore leads to the amino acid substitution R249S [63, 64].
Chronic infection with HBV and HCV viruses, and oxyradi-
cal disorders including hemochromatosis, also generate reac-
tive oxygen/nitrogen species that can both damage DNA and
mutate cancer-related genes such as TP53 [63, 65]. In geo-
graphic locations without AFB1 exposure as Western coun-
triesTP53mutationsarefoundinaround20%ofHCCs[50].
Except TP53, research is conducted on other genes such
as AXIN1 and CTNNB1 to determine the role of their mu-
tations in the occurrence of HCC. Their role seems to be less
in HCC because they are found to rarely mutate and then
occur in less than 10% of HCC [28, 50, 56].
4. HCCStaging
Staging system of cancers for classiﬁcation of HCC provides
a guide to patient assessment and to direct therapeutic
interventions[66,67].Itisthenakeytopredicttheprognosis
of patients with cancer, to stratify the patients according to
prognostic variables in the setting of clinical trials, to allow
information exchange among researchers [68]. However,
there is no general consensus in the diﬀerent system and
geographic variations exists [41]. For HCC, several staging
systems (Table 1) have been developed and generally take
into account tumor characteristics such as tumor size, num-
ber, vascular invasion and metastasis, and also the severity of
the underlying cirrhosis [1, 69]. For a classiﬁcation system
to allow a reliable assessment of prognosis, two conditions
are necessary: prognosis between two stages should be as dif-
ferent as possible (discriminatory ability) and as identical as
possible within the same stage (homogeneity). Moreover, the
survival of patients in favorable stages must be greater than
unfavorable stages (monotonicity of gradients) [70]. Among
the staging systems, the most used for the HCC are Okuda
classiﬁcation, TNM classiﬁcation, CLIP classiﬁcation, BCLC
classiﬁcation, French classiﬁcation, CUPI classiﬁcation, and
JIS classiﬁcation (Table 1).
4.1. Okuda Classiﬁcation. Established in 1985 from 850 cases
of hepatocellular carcinoma, Okuda classiﬁcation is one of
the most commonly used staging systems in the world. It
includes both parameters related to the tumors stage (more
or less than 50% of liver area involved) and functional status
such as albumin, ascites, and bilirubin. However, it does
not include important prognostic parameters such as the
unifocal, multifocal, or diﬀuse state of the tumor, existence
of a portal vein thrombosis or distant metastasis and the
alpha-fetoprotein (AFP) rate. It is generally used in patient
stratiﬁcation with advanced or symptomatic stage HCC
(Okuda III); so it is unsuitable for the distinction of patients
at more favorable prognosis [66, 68, 70].
4.2. TNM Classiﬁcation. Proposed as the best staging system
to assess outcome of HCC patients undergoing resection and
based on tumor size (T1 to T4), number, vascular invasion,
regional node status, and distant metastases, TNM is only
based on tumor characteristics. It ignores the severity of un-
derlying chronic liver disease, showing poor prognostic in
patient undergoing curative treatment. TNM has been re-
vised and has become American Joint Committee on Cancer
(AJCC) TNM (Tumor, Node, Metastasis) staging system.
Then, the ﬁbrosis is taken into account in addition to the
morphology of tumors [1, 66, 71].
4.3. CLIP (Cancer of the Liver Italian Program) Classiﬁcation.
made from a retrospective analysis of 1990 to 1992 ofISRN Oncology 5
Table 1: Staging system and prognostic variables used in the staging systems in HCC (adapted from [68] with permission of the HPB
(Oxford) journal).
Classiﬁcation Type Stage Tumor stage Liver function Health
status
Okuda stage System Stage I, II, III 50% liver involvement
Bilirubin
Albumin
Ascites
—
French Score
A: 0 points;
B: 1–5 points;
C: 56 points
Portal invasion AFP
Bilirubin
Alkaline
phosphatase
Karnofsky
C L I P S c o r e 0 ,1 ,2 ,3 ,4 ,5 ,6 Portal invasion 5/450%
liver involvement AFP Child-Pugh —
BCLC staging Staging
0: Very early
A: Early
B: Intermediate
C: Advanced
D: End-stage
Portal invasion
Metastases
Morphology
Okuda
Child-Pugh
Portal
hypertension
Bilirubin
PST
TNM staging System Stage I, II, III
Morphology
Vascular invasion
Metastases
Fibrosis —
CUPI Score
Low risk: score ≤1
Intermediate: score 2–7
High: score ≥ 8
TNM
AFP Ascites Bilirubin Symptoms
JIS Score Stage I, II, III, IV TNM Child-Pugh —
Table 2: Variables used in the Child-Pugh score (source [8]).
Measure 1 point 2 points 3 points
Total bilirubin, μmoL/L
(mg/dL) <34 (<2) 34–50 (2-3) >50 (>3)
Serum albumin, g/L >35 28–35 <28
INR <1.7 1.71–2.20 >2.20
Ascites None Mild Severe
Hepatic encephalopathy None Grade I-II
(or suppressed with medication) Grade III-IV (or refractory)
Table 3: Interpretation of the Child-Pugh score (source [8]).
Points Class One-year
survival
Two-year
survival
5-6 A 100% 85%
7–9 B 81% 57%
10–15 C 45% 35%
parameters inﬂuencing survival of HCC patients and vali-
dated by authors and others groups in several prospective
studies, CLIP score combines parameters predictive of
survival: severity of liver disease (Child-Pugh score Tables 2
and 3), and tumor characteristics as tumor morphology,
AFP rate, existence of portal vein thrombosis and classiﬁes
patients with HCC into six groups. Compared to the Okuda
or TNM, Clip improves the prognostic accuracy because
all predictor variables are considered as adverse prognostic
characteristic in patients with HCC. CLIP has limitations
when considered in HCC patients diagnosed in the early
stage; survival diﬀerence for patient groups 4 to 6 is less
discriminatory [68, 72–74].
4.4. BCLC (Barcelona Clinic Liver Center). This staging sys-
tem classiﬁes patients according to the evolutionary course
of the tumor and liver disease, thus allowing for a conﬁdent
predictive life expectation and choice of convenient treat-
ment modality for patients in each group [75]. Very early/
early stage (A) with asymptomatic early tumors (single tu-
mor less than 5cm), without portal hypertension, and with-
out abnormal bilirubin are suitable for radical therapies such
as resection, transplantations, or percutaneous treatments.
Intermediate stage (B) with asymptomatic multinodular
HCC is suitable for chemoembolization treatment. In ad-
vanced stage (C) with symptomatic tumors and/or an in-
vasive tumoral pattern (alteration of the general state/portal
vein thrombosis/metastases), the sorafenib is the standard
treatment proposed. In end-stage disease with patients in a
terminalstageofHCC,symptomaticcareismostappropriate
[76–78].6 ISRN Oncology
HCC
Stage 0 Stage A–C Stage D
PST 0, Child-Pugh A, Okuda 1 Okuda 1–2, PST 0–2, Child-Pugh A–B Okuda 3, PST >2, Child-Pugh C
Very early stage (0)
Carcinoma in situ
Early stage (A)
1 HCC or 3 nodules
Intermediate stage (B)
Multinodular, 
Advanced stage (C)
Portal invasion,
N1, M1, PST 1-2
Terminal stage (D)
I HCC
Portal pressure/bilirubin
Increased Associated diseases Portal invasion, N1, M1
Normal No Yes No Yes
Resection Liver transplantation∗ PEI/radiofrequency Chemoembolization New agents
Curative treatments Randomized controlled trials Symptomatic
treatment
1 HCC <2cm
3 nodules <3cm
<3cm, PST 0 PST 0
Figure 2: Barcelona-Cl´ ınic Liver Cancer staging classiﬁcation and treatment schedule. PST: performance status test. N: nodules. M:
metastases. PEI: percutaneous ethanol injection. ∗Cadaveric liver transplantation or living donor liver transplantation. (Source [78] with
permission of The Lancet Journal.)
BCLC is the only system of stratiﬁcation in which
each group is correlated with a mode of speciﬁc treatment
(Figure 2). This advantage of linking the stage of HCC pa-
tient with appropriate treatment allows it to oﬀer as the best
classiﬁcation system validated especially in patients with ear-
ly HCC [68].
4.5. French Classiﬁcation. Five factors prognostics are taken
into account in classifying patient with HCC: Karnofsky
index, serum bilirubin reﬂecting liver excretion or biliary
function, serum alkaline phosphatase related to the growth
rateofHCC,serumalpha-fetoproteinreﬂectingthedegreeof
cellular diﬀerentiation and then the spreading of the tumor,
and ultrasonographic portal obstruction. The prospective
study was done in seven hundred and sixty-one (761) pa-
tients with hepatocellular carcinoma from 24 western med-
ical centers enrolled over a 30-month period (from 15 July
1990 to 1 December 1992). Patients were divided into three
groups (A, B, C) according to the increasing estimated risk of
death (for instance, less than 5% at 2 years in group C and
more than 50% in group A). This classiﬁcation performed
well as a single independent predictor of survival in the
nonsurgical group according to Cox’s regression analysis,
probably because it also considers the patient’s general
health (Karnofsky index), unlike the Okuda, CLIP, and CUPI
scores. Because of not taking into account tumor extension
variables, it has limited prognostic capacity in patients with
early HCC [68, 79].
4.6. CUPI (Chinese University Prognostic Index). It has been
investigated in Hong Kong from 1996 to 1998 on 926 ethnic
Chinese patients who were diagnosed with HCC. Hepatitis B
was detected in 79% of patients. In this system, patients were
divided into three diﬀerent groups, and six prognosis factors
were taken into account by adding the following factors
into the TNM staging system: total bilirubin, ascites, alkaline
phosphatase, alfa-fetoprotein, and asymptomatic disease on
presentation.Asaconclusion,inpatientswithmainlyhepati-
tis B-associated HCC, the CUPI was more discriminant than
the TNM staging system, the Okuda staging systems, or the
CLIP prognostic score in classifying patients into diﬀerent
risk groups and was better at predicting survival. However,
for wide usage, the CUPI needs to be validated by diﬀerent
cohorts of patients [80].
4.7. JIS Score (Japan Integrated Staging). It is a new staging
system proposed in Japan and based on the Liver Cancer
Study Group of Japan (LCSGJ). It has been investigated in a
totalof722patientswithHCCcoveringaperiodoftenyears.
It accounts for both Child-Pugh classiﬁcation and Japan
tumour node metastasis (TNM) staging. The JIS scoring is a
stagingsystemdevelopedtoclassifyearly-stageHCCpatientsISRN Oncology 7
requiring curative treatment, such as surgery and medical
ablation. The prognostic predictive power of the JIS score
was equal to the CLIP score and was better than the original
BCLC staging classiﬁcation [72, 81–83].
A consensus seems to be necessary to standardize the
management of patients with hepatocellular carcinoma. For
that, new strategies must be implemented in diversifying
the classiﬁcation criteria. Histological causes and molecular
changes leading to HCC should provide new tools to be in-
cluded in the stratiﬁcation criteria.
5.HCCDiagnosisandSurveillance
HCC diagnosis is considerable interest to clinician’s evalua-
tion patients with liver cirrhosis [84]. Generally, HCC ap-
pears with setting of cirrhosis with underlying chronic viral
hepatitis (B or C) or alcoholism and more recently with
nonalcoholic steatohepatitis [85]. In many patients, HCC is
asymptomatic and then is diagnosed in an advanced stage.
That is why, for cirrhotic patients, surveillance is strongly
recommended to detect early HCC allowing an increase of
patientssuitableforcurativetreatmentandthenlimittumor-
related dead. Symptoms of HCC are commonly related to
those of their chronic liver disease and include pain in the
upper abdomen on the right side, a lump or a feeling of
heaviness in the upper abdomen, swollen abdomen (bloat-
ing), anemia, weight loss, weakness or fatigue, nausea and
vomiting,yellowingskinandeyes,palestools,anddarkurine
from jaundice caused by invasion of the biliary tree, fever,
pain born in case of metastases [86–88].
The diagnosis criteria of HCC consist in the detection of
the index lesion, intrahepatic lesion staging, and an assess-
ment for extrahepatic metastasis [84]. An international con-
sensus statement has been formulated by the EASL (Euro-
pean Association for the Study of Liver) to regulate the diag-
nosis approach and surveillance algorithm for HCC patients
and has been updated in the American Association for the
Study of Liver Disease 2005 guidelines (AASLD) [89, 90].
Identiﬁcation of HCC in patients with cirrhosis was based
on the radiological and histological criteria, and recom-
mendations upon detection of nodular lesion during US
surveillance were based on the size of the nodule [91].
AFP and live Us are widely used for HCC surveillance
that must be done every 6 months since this time is con-
sidered to be the average time for tumor duplication [92].
AFP is used as a screening test because HCC may secrete ele-
vated rate of AFP. Many studies of AFP in HCC surveillance
revealed that its sensitivity is estimated at 39-64%, it
speciﬁcity to 76–91%, and its positive predictive value to 9–
32%. The speciﬁcity and sensitivity depend on the AFP cut-
oﬀlevelchosenforthediagnosis.Acut-oﬀvalueof20ng/mL
corresponded in a sensitivity of 64% and a speciﬁcity of
91%, while a sensitivity of 17% and speciﬁcity of 99% for
thecut-oﬀvalueof400ng/mL.Generally,diagnosisconﬁrms
HCC in values over 400ng/mL, although this value was only
found in 20% of HCC patients. AFP level is usually cor-
related to tumor morphology. Tumor less than 2cm is rarely
detectable. For these remarks, AFP is not considered as a
suitable test [5, 18, 88, 93]. Us is much better screening
tool than AFP. Since new methods are introduced such as
contrast-enhanced Us, detection has been improved with
better sensitivity and speciﬁcity [88, 94]. Cost-eﬀectiveness
of surveillance for early detection is debatable. It is found to
allow patients diagnosis in a resectable stage improving then
the long-term survival [89, 95].
EASL diagnosis approach proposed for nodules >2cm
noninvasive diagnosis of HCC can be done with arterial hy-
pervascularization into two modalities, or in one imaging
technique. Associated with an AFP level ≥400ng/mL in cir-
rhotic liver, Us, spiral CT, MRI, and angiography are used to
evaluate the vascularity of the hepatic nodules. Under these
conditions, biopsy is not required avoiding the 10–20% false
negative rate from histological samples and the risk for tu-
mor seeding.
Nodules <1cm, found to be malignant in less than 50%
of cases and diﬃcult to be eﬀectively diagnosis even by
biopsy, a repeated ultrasound screening every 3 months, are
r e c o m m e n d e du n t i lt h e1c ms i z ei sr e a c h e d .
Nodules between 1 and 2cm are more likely to be HCC.
Two imaging dynamic studies can be considered to be HCC,
and diagnosis conﬁrmation is required using biopsy or ﬁne-
needle aspiration or both of them. In these nodules 30-40%
false negative rate are generally noted with a tumor seeding
[4, 87–89, 91, 93, 96, 97].
6. Therapy
Therapeuticapproachesareconventionallyclassiﬁedascura-
tive and palliative. The choice of treatment depends on the
tumor characteristics, liver function, and presence or not of
metastasis or vascular invasion. Curative treatments are sur-
gical resection, liver transplantation, and percutaneous abla-
tion and aim to improve survival. Palliative approaches in-
clude systemic chemotherapy, immunotherapy, and hor-
monal compounds. Curative options can be considered in
early diagnosis of HCC, which is generally deﬁned as a HCC
with a solitary tumor <5cm, or up to 3 nodules <3cmeach
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HCC patients will be candidates from curative treatment. In
advanced stage, local extrahepatic spread, distant metastases,
or in HCC patients not eligible for surgical approaches, pal-
liative therapies are proposed.
6.1. Liver Resection. Noncirrhotic patients or Child-Pugh
A cirrhotic patients with a well-preserved liver function, a
single nodule, and normal portal pressure are eligible for
surgicalresection[98–100].Asaresultoftheseguidelinesfew
HCC patients beneﬁt from this method. In Asia where HCC
has a high incidence, only 10–15% of newly diagnosed pa-
tients undergo resection therapy. In Western countries, only
5–10%arecandidatesforresectionsurgery.Diﬀerencesintu-
mor biology, in health-care standards, and the HCC-related
etiology which is HBV-infection especially in Asia explain
in large part these comments [13, 41]. Long-term survival
of 5 years can be achieved in 60–70% of patients who have
undergone resection depending on the stage of disease. After
treatment with surgical intent, there is a very high risk of8 ISRN Oncology
recurrence, 70% at 5 years, and within 2 years in majori-
ty. Recurrence reasons are complex and depend on the size
and diﬀerentiation of tumor, intrahepatic metastases un-
detectable at resection time, vascular invasion, and satellites
nodules. A repeated resection is generally possible in only
20% of cases. Therefore, these patients should be evaluated
for eﬀective prevention of recurrence using adjuvant treat-
ment such as interferon, lipiodol, and adoptive immuno-
therapy, retinoids (polyprenoic acid) even if these promising
results require further validation [20, 88, 89, 93, 101, 102].
6.2. Liver Transplantation. Orthotopic liver transplantation
(OLT) is the curative options in which both the tumor and
the underlying liver disease are removed. Therefore, it is
the treatment of choice for patients with hepatic cirrhosis-
related hepatocellular carcinoma [103–105]. Patients with
HCC meeting the Milan criteria [106] which are single
nodule ≤5cm in diameter or up to 3 separate lesions all
less than 3cm, no proven vascular invasion, no nodal or dis-
tant metastases are appropriated candidates for OLT. Under
these criteria, an overall and recurrence-free survival rates
at 4 years of 85% and 92% have been shown. With these
convincing results, much research has been done to improve
the criteria for selecting patients for OLT. Using less stringent
criteria, which are a maximum nodule size of 6.5cm or 2
lesions <4.5cm diameter with a total tumor diameter <8cm,
the group from the University of California at San Francisco
(UCSF) has demonstrated a 5-year survival of 75% [107]. In
most of the liver transplantation, the liver is from a deceased
donor. This constitutes a major drawback of this treatment
because of the scarcity of donors that is crucial in Asia. As a
consequence, the MELD (Model of End-Stage liver Disease)
scoring system has been adopted to allocate organs for the
patient in waiting list for liver transplantation. This score
can range from 0 to >40 points and is indicative of the risk
of death without liver transplantation. Patients with higher
score are priority and receive the ﬁrst oﬀers [108–112]. To
overcome the scarcity of deceased donors, the notion of
living donor liver transplantation (LDLT) has been adopted
andhasallowedtofacelongwaitingtimesfordeceaseddonor
liver grafts. Several retrospective studies have shown that
LDLT for HCC has a similar survival to that of deceased
donor transplantation [113, 114].
6.3. Percutaneous Ablation. Patients with early HCC who
are not candidates for resection or liver transplantation,
are treated preferentially with percutaneous ablation, that is
consideredasaminimallyinvasiveoptionwithlowmortality,
low rates of complications, and good outcomes in overall
survival [115–117]. Percutaneous ethanol injection (PEI)
and radiofrequency thermal ablation (RFA) are the most
widely procedures used in ablation therapy and are done
under guidance imaging. PEI was the ﬁrst standard ablation
treatment, but few years later RFA was recommended as the
best option for percutaneous ablation. In most institutions
in Asia, RFA has replaced the PEI [13, 89, 118]. New ablative
therapies have been introduced such as microwave ablation,
cryoablation, and high-intensity focused ultrasound abla-
tion. Child-Pugh A patients are the best candidates with a
5-year survival of 50%. The most frequent drawback for
percutaneousisthehighrateofrecurrencewhichisevaluated
in PEI at 33–43% [117].
6.4. Palliative Therapy. Due to the implementation of pre-
vention programs for HCC, patients are usually diagnosed
in early stage. Nevertheless, some are detectable at an
intermediate or advanced stage with preserved liver function
or not, multinodular disease exceeding the Milan criteria,
withorwithoutsymptomsorextrahepaticspreadmanifested
by absence of portal/node invasion or distant metastasis. For
these patients, palliative therapies are proposed to reduce
symptoms related to disease progression and improve sur-
vival [89, 118]. The general principle of palliative treatment
is to prevent the blood supply to the HCC by blockage of
the arterial system of liver. These treatments include tran-
sarterial embolization (TAE), transarterial chemoemboliza-
tion (TACE), intra-artery chemotherapy (IACT), and radio-
therapy (external and internal) [119, 120]. They can be used
as bridge to liver transplantation.
TAE and IACT are known to have an anticancer activity
but no eﬀect in increasing survival [4]. TACE is the most
widelyusedforunrespectableHCCandoneofthemostused
techniques to control liver cancer around the world. [121].
Intra-arterialdeliveryofchemotherapeuticagents(especially
doxorubicin combined with others agents) and blocking
(embolizing) the small blood vessels feeding the tumor are
the process treatment used by TACE. Patients with multiple
diﬀusetumorsoruninodularlargerthan5cm,wellpreserved
liver function, and absence of portal vein invasion or Child-
Turcott Plug class C are main candidates for this treatment
[87]. Patient’s selection is essential for TACE because it
avoid side eﬀects leading to liver failure and death [89].
Randomized control trials have shown beneﬁt of TACE. An
objectiveresponselasting1–6monthsin35%ofpatientsand
improvement survival rate in unresectable HCC have been
proven [4].
Patients in intermediate stage to advanced stage with
portal vein thrombosis (PVT) can be treated by yttrium-90
radioembolization (90Y-RE). It consists of direct injection
into the blood vessels feeding the cancers with a radioactive
molecule yttrium-90 impregnated glass microspheres or re-
sin beads. The radiation particles can then kill tumor cells
withinadistanceof2.5mmfromthemsothatanypartofthe
cancer fed by tiny blood vessels will be exposed to the radia-
tion. Hence, tumor growth is inhibited and liver function
remains preserved. Recipient patients respond to treatment
with an improved quality of life. It can be used as bridge
to RFA and resection. Comparison between the survival of
HCC patients in advanced stage either not treated or treated
withineﬀectivesystemicagents,survivalafter(90)Y-REisen-
couraging and warrants future clinical trials [122–125].
6.5. Systemic Therapies. Parallel to the development of re-
search concerning pathological and histological pathways
leading to HCC, many drugs and hormonal therapy have
been tested as agents inhibiting important signaling path-
ways in tumor cells and also angiogenesis in systemic therapy
for HCC. Patients in intermediate or advanced stage who doISRN Oncology 9
not undergo curative surgical treatment and ablative tech-
niques are candidates for these therapies. Systemic therapies
have not unfortunately provided beneﬁt eﬀect or increased
survival for patients with advanced HCC. Several clinical tri-
alshavebeenconductedontheseagentssearchinganoptimal
therapy against advanced HCC, but there is no currently
deﬁned as a standard formula eﬀective against advanced
HCC. They can be used as single or combined hormonal or
chemotherapy. The most used is the multikinase inhibitor
sorafenib that was approved by the European Medicines
Agency (EMEA) and the US Food and Drug Administration
(FDA). These promising beneﬁts in patients with metastatic
disease need further evaluation. Other therapeutic agents
such as doxorubicin, epirubicin, mitoxantrone, cisplatin,
gemcitabine, capecitabine, 5-Flu, Tamoxifen, and placebo.
have been also used as single agent against advanced HCC.
Some combined agents against HCC have been investigated,
and the most known are cisplatin, doxorubicin, 5-Flu, and
interferon-α (PIAF), gemcitabine and oxaliplatin (GEMOX),
oxaliplatin and 5-Flu/leucovorin (FOLFOX), capecitabine
and oxaliplatin (XELOX). The results vary depending on the
research groups, countries, and characteristics of the patients
tested [10, 41, 126–130].
7. Conclusion
The HCC remains a malignant disease leading to death.
Signiﬁcant progress has been made in the management of
the disease. Because of its complexity, a multidisciplinary
approach must be implemented to support the diﬀerent as-
pects in HCC. A better control of epidemiology should
better sit prevention programs in at-risk populations. A
better understanding of the molecular and histological res-
ponsible for the occurrence of the disease should allow the
development of new diagnostics and treatments more ef-
fective in the treatment of HCC.
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